KOSTLIVY, Tomas, Petr SKOPEK, Pavel KLAIL, Hana LAIEROVA, Alena SKALOVA, Břetislav GÁL, Radek KUCERA, Vaclav SIMANEK and David SLOUKA. Newborn Hearing Screening - An Implementation Analysis. In vivo. ATHENS: Greece : International Institute of Anticancer Research, 2024, vol. 38, No 4, p. 1939-1946. ISSN 0258-851X. Available from: https://dx.doi.org/10.21873/invivo.13650.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Newborn Hearing Screening - An Implementation Analysis
Authors KOSTLIVY, Tomas (203 Czech Republic), Petr SKOPEK (203 Czech Republic), Pavel KLAIL (203 Czech Republic), Hana LAIEROVA (203 Czech Republic), Alena SKALOVA (203 Czech Republic), Břetislav GÁL (203 Czech Republic, belonging to the institution), Radek KUCERA (203 Czech Republic), Vaclav SIMANEK (203 Czech Republic) and David SLOUKA (203 Czech Republic).
Edition In vivo, ATHENS, Greece : International Institute of Anticancer Research, 2024, 0258-851X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30206 Otorhinolaryngology
Country of publisher Greece
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.300 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.21873/invivo.13650
UT WoS 001266321000049
Keywords in English Newborn; hearing screening; hearing loss treatment
Tags 14110126, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 15/8/2024 10:22.
Abstract
Background/Aim: Hearing impairment affects a small but significant percentage of newborns (0.1-0.4%). Newborn hearing screening (NHS) is recommended for early detection and treatment. The implementation of NHS can vary among countries. In this study, we present the methodology, organization, and technical requirements of NHS. This study analyzed results from a tertiary hospital, identified issues, and proposed solutions. Patients and Methods: In the studied region, there are five maternity hospitals and a perinatal intensive care center and in 2020, there were 5,864 live births. Screening is performed at three levels. The first screening is conducted on the 2nd-3rd day of a newborn's life in a maternity hospital, the first rescreening on the 3rd-6th week at a relevant ENT department, and the second rescreening on the 3rd-6th month of life at the regional screening center where the central database is also held. Results: In the studied region, 5,793 out of 5,864 (98.79%) newborns received NHS in 2020. Of these, 120 (2.07%) were tested positive on their first screening. Ninetyfour patients (78.3%) of those attended the ENT department for a first rescreening. Thirty-four patients (0.59% of total) were tested positive again and referred to the regional screening center. Out of the 27 patients who attended the second rescreening, four (0.07% of the total) were ultimately diagnosed with hearing impairment. Conclusion: Our study found that newborn hearing screening (NHS) in our region achieved a high compliance rate of 98.8% for initial screenings in 2020. However, challenges remain in the rescreening process due to data management issues, interregional cooperation, and public awareness. The recent implementation of mandatory screenings, updated guidelines, and a centralized database is expected to enhance the effectiveness of NHS. Further research is needed to evaluate these improvements.
PrintDisplayed: 6/9/2024 17:26